Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., a move that establishes the company as the sole global rights holder of Telomir-1 (Telomir-Zn) and eliminates prior geographic fragmentation of the asset. The transaction, approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress.
The acquisition strengthens Telomir's position as it advances Telomir-Zn toward the clinic following a recent Investigational New Drug (IND) submission for the treatment of advanced and metastatic triple-negative breast cancer. The company plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The consolidation of global rights to Telomir-1 is significant for investors and the industry as it removes previous uncertainties around regional licensing and allows for a unified development strategy. The additional milestone-based funding provides financial support for clinical progress, potentially accelerating the timeline for Telomir-1 to reach patients. Triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options, making the advancement of new therapies particularly impactful.
For more information, visit https://ibn.fm/DcY4o for the full press release and https://ibn.fm/TELO for the latest news and updates relating to TELO.
